Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 7/20 | 0.39 |
| ▸ | Q9HBH1 | 3/20 | 0.38 | |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067258 | 0.84 | PDF (0.38) | BMP1PDF | |
| SCHEMBL4059517 | 0.82 | BMP1 (0.53) | BMP1PDFMMP12 | |
| SCHEMBL16898351 | 0.82 | BMP1 (0.53) | BMP1PDFMMP12 | |
| SCHEMBL4249133 | 0.76 | — | — | |
| SCHEMBL1596449 | 0.69 | GAA (0.39) | BMP1MMP12 | |
| SCHEMBL1596446 | 0.69 | GAA (0.39) | BMP1MMP12 | |
| SCHEMBL1597846 | 0.68 | CA1 (0.54) | BMP1PDFMMP12 | |
| SCHEMBL1597844 | 0.68 | CA1 (0.54) | BMP1PDFMMP12 | |
| SCHEMBL1597847 | 0.68 | CA1 (0.54) | BMP1PDFMMP12 | |
| SCHEMBL6024181 | 0.67 | BMP1 (0.44) | BMP1PDFMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585757-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-08-01 | — | — | EP | claimed |
| US-7442793-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-28 | — | — | US | claimed |
| US-20070173542-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2007-07-26 | — | — | US | claimed |
| EP-1585757-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1585757-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7442793-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070173542-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2007-07-26 | — | — | US | disclosed |
| EP-1585757-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004052919-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173542-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | BMP1 1590/4885PDF 1/4885MMP12 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.